MedCity News
OCTOBER 16, 2022
As society becomes more open to and reliant on these tools, it is the responsibility of technology companies, especially those tasked with assisting people’s mental health, to build and maintain artificial intelligence and machine learning models that adapt alongside societal needs.
European Pharmaceutical Review
OCTOBER 20, 2022
In recent years there has been significant development within the cell therapy field, as chimeric antigen receptor (CAR) T-cell therapy demonstrated an ability to transform the treatment of patients with haematological malignancies. Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 19, 2022
Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of precision genetic medicine firm Akouos for a total deal value of up to nearly $610m or up to $15.50 for each share in cash. The deal comprises an acquisition value of $12.50 for each share in cash payable at closing along with one non-tradeable contingent value right per share (CVR) of up to another $3 in cash.
pharmaphorum
OCTOBER 20, 2022
And the LIVE coverage continues as we head into Day Two… This day is set to hold even more points of interest, with the demonstration ‘CX innovation: building experiences that work for customers’ (moderated by Healthware Group’s global head of digital strategy and customer engagement Yannick Valenti), as well as the masterclass ‘How to maximise learning science to affect behaviour change’ with Meducate Global’s president, Lawrence Sherman, and MD of Healthware MedComms & SWM, Francis M
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
OCTOBER 17, 2022
Eyenuk, a company that makes technology for eye screenings, raised $26 million in a Series A funding round, bringing its total funding to more than $43 million. Research shows that the company’s AI system is more accurate in detecting diabetic retinopathy than a clinical examination from a general ophthalmologist or a retina specialist.
European Pharmaceutical Review
OCTOBER 17, 2022
Novartis announced that The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Pluvicto ® radioligand therapy for treatment of patients with prostate cancer. Pluvicto combines a targeting compound (ligand, in this case directed to PSMA) with a therapeutic radioisotope (in this case lutetium-177).
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Medgadget
OCTOBER 19, 2022
Researchers at Hokkaido University in Japan have developed a biomarker test for Alzheimer’s disease that detects amyloid ? binding exosomes in a blood sample. While amyloid ? plaques in the brain are characteristic of Alzheimer’s, these researchers have previously reported that amyloid ? build-up in the brain is associated with an increase in amyloid ?
MedCity News
OCTOBER 16, 2022
Enliven Therapeutics’ reverse merger with Imara will form a combined company with $300 million to finance clinical development of new cancer drugs. Its most advanced program is a tyrosine kinase inhibitor for chronic myeloid leukemia.
pharmaphorum
OCTOBER 17, 2022
Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. Elinzanetant is already being tested in the OASIS trials for VMS associated with menopause – an indication in which Bayer is in a head-to-head race with Astellas and its fezolinetant drug candidate – and breast cancer could represent a sizeable additional patient population for the drug.
Pharmaceutical Technology
OCTOBER 18, 2022
A new study identifies a novel cerebrospinal fluid biomarker for Parkinson’s disease, expanding the scope of possible drug targets. Last week, Nature magazine published a paper detailing an in-situ study of Parkinson’s disease (PD), showing protein structural changes in cerebrospinal fluid (CSF) between healthy individuals and Parkinson’s patients. There is potential that these structural changes could allow for a new method of differentiating different disease subtypes, thus expanding the scope
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Medgadget
OCTOBER 17, 2022
Medical researchers at Washington University School of Medicine in St. Louis have developed a fluorescence imaging technique that allows them to illuminate a tumor in situ and calculate its depth below the surface of the body. The technique could assist surgeons in accurately removing a tumor and successfully excising an appropriate margin of healthy tissue to reduce the chances of tumor recurrence.
MedCity News
OCTOBER 17, 2022
Healthcare organizations must ensure they have a data-literate workforce that is confident in using the data and is empowered in using it to make decisions. Here are some best practices that hospitals can implement to better empower their employees to make data-driven decisions.
European Pharmaceutical Review
OCTOBER 17, 2022
Included in this issue: PATENTS. Patents: a necessary evil? David Elder, David P Elder Consultancy. MICROBIOLOGY. Pharma’s green mission: trends in bacterial endotoxin testing. Hannah Balfour. Lindsey Silva, Carmen Marín Delgado de Robles, Viviane Grunert da Fonseca and Evelyn Der, Roche Group. QA/QC. An Annex 1 and Pharma 4.0 perspective on water quality.
pharmaphorum
OCTOBER 19, 2022
Frontiers Health 2022 in Milan is LIVE! Opening Day One will be Healthware Group’s CEO and founder Roberto Ascione and WTF Health’s founder and host Jessica DaMassa. The day’s keynote addresses will include ‘The H is for humanity’ by MD of Taliossa Tony Estrella and founder and trustee of Rachel’s House Lynna Chandra, as well as ‘Creative disruption in delivering novel VR solutions in pain: evidence, teamwork, and delivery’ by Christopher Eccleston, professor of medical psychology at the U
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Medgadget
OCTOBER 17, 2022
Researchers at RMIT University in Melbourne, Australia, have developed an app that is intended to provide early diagnosis for Parkinson’s disease and severe COVID-19. The artificial intelligence-powered technology works by analyzing voice recordings, having previously been trained to recognize the vocal hallmarks of these diseases by listening to recordings of patients.
MedCity News
OCTOBER 16, 2022
With so much supporting data and real-world success, it is time for catheter ablation to become a routine treatment option for patients suffering from arrhythmias.
European Pharmaceutical Review
OCTOBER 18, 2022
Kite announced that the European Commission (EC) has approved the use of cell therapy Yescarta ® for treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), who relapse within 12 months or are refractory to, first-line chemoimmunotherapy. The approval is based on results from the Phase III ZUMA-7 study, the largest and longest trial of a CAR T-cell therapy versus standard of care (SOC) in this patient population.
PharmaVoice
OCTOBER 17, 2022
Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Technology
OCTOBER 17, 2022
Novo Nordisk has concluded the acquisition of all outstanding shares of common stock of clinical-stage biopharmaceutical company Forma Therapeutics for $20 for each share in cash or a deal totalling $1.1bn. In September, Novo Nordisk entered a definitive agreement to acquire Forma. With the conclusion of the merger, Forma became Novo Nordisk’s fully-owned subsidiary. .
MedCity News
OCTOBER 16, 2022
NeuroFlow, a Philadelphia-based provider of behavioral health integration software, recently raised $25 million in growth capital. The startup differentiates itself from the sea of mental health-focused startups in the digital health world because of its ability to combine effective patient engagement technology with decision support tools for clinical staff, according to COO Adam Pardes.
European Pharmaceutical Review
OCTOBER 20, 2022
Apogenix , a biopharmaceutical company developing next generation immunotherapeutics, announced that asunercept showed statistically significant benefits for hospitalised COVID-19 patients in the ASUNCTIS trial. Apogenix’s lead immunotherapy candidate, asunercept is a fully human fusion protein, consisting of the CD95 receptor and an IgG1 antibody. It is being developed for the treatment of solid tumours, haematological malignancies and viral infections such as COVID-19.
PharmExec
OCTOBER 19, 2022
The acquisition by ILSL Inc., a subsidiary of Indegene Private Limited, augments Indegene’s commercialization portfolio spanning drug discovery and development to marketing and sales, adding brand strategy, market development capabilities, and patient engagement platforms.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Medico Reach
OCTOBER 17, 2022
Grand View Research published a report recently that captured some interesting highlights about the orthopedic medical device industry. The article puts the global market size for the sector at $40.9 billion in 2021, with a compounded annual growth rate (CAGR) of 3.1% from 2022 to 2030. According to another study , musculoskeletal conditions, currently affecting 1.71 billion people, will drive the market revenue even higher.
MedCity News
OCTOBER 16, 2022
The 10% increase is the largest in almost 15 years, the Willis Towers Watson survey found. Most of the insurers, or 75%, blamed the overuse of care for the rise in medical costs.
Legacy MEDSearch
OCTOBER 18, 2022
Axoft, a neurotechnology company, launched and announced FDA Breakthrough Device designation for its brain-machine interface (BMI) to better treat neurological disorders. The company secured $8 million in capital to fund pre-clinical studies with the FDA and to scale up prototypes of its neural implants “as soft as the brain.” The seed round investment, led by The Engine, the venture firm spun out of MIT that invests in early-stage Tough Tech companies, included investors: Ab Initio Capital, Dec
pharmaphorum
OCTOBER 21, 2022
The UK company reveals the results from a partner-led survey to discover the rates of vaccination for adults, why levels are lower than expected, and what can be done to improve this. Ben Hargreaves examines the reasons supplied by the survey and why GSK is invested in the answers. The emergence of COVID-19 meant that public awareness around vaccination and its importance in fighting the spread of infectious disease has increased rapidly.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
PharmaVoice
OCTOBER 20, 2022
The healthcare giant showed pharmaceutical gains, but that's no thanks to the economic environment of persistent inflation and a strong U.S. dollar.
MedCity News
OCTOBER 17, 2022
Many Medicare Advantage enrollees choose their plans because they offer more benefits than traditional Medicare and have limits on out-of-pocket costs. Traditional Medicare plans, however, provide more options for doctors, hospitals and providers.
European Pharmaceutical Review
OCTOBER 20, 2022
City of Hope , one of the largest cancer research and treatment organisations in the US, announced that the first patient to receive novel cancer medicine AOH1996, is doing well. The Phase I clinical trial is open at City of Hope Los Angeles. Its objective is to determine the maximum tolerated dose of the investigational pill, AOH1996, and to evaluate the medicine for preliminary efficacy.
pharmaphorum
OCTOBER 21, 2022
Young adults with depression have been treated effectively with a cognitive behavioural therapy (CBT) course – delivered via text message – in a pilot study conducted by researchers in the US. The trial looked at a four-week CBT course adapted from a face-to-face programme to work via text messages, followed by a four-week follow-up period, in around 100 young adults in the US with at least one symptom of moderate depression and no recent history of antidepressant therapy.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Expert insights. Personalized for you.
145 
Let's personalize your content